Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPHNASDAQ:AUPHNASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$24.41-0.4%$26.77$22.64▼$53.96$1.16B0.79465,504 shs460,186 shsAUPHAurinia Pharmaceuticals$8.24+1.5%$8.02$4.99▼$10.67$1.13B1.21.35 million shs1.07 million shsSNDXSyndax Pharmaceuticals$14.15+3.3%$12.96$9.66▼$25.07$1.22B1.281.61 million shs3.03 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+0.37%+2.38%-13.82%-32.73%-41.69%AUPHAurinia Pharmaceuticals+1.50%+2.92%-2.05%-0.25%+62.08%SNDXSyndax Pharmaceuticals+2.09%+6.04%+3.95%-3.79%-35.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPHAmphastar Pharmaceuticals4.5045 of 5 stars3.03.00.03.73.64.21.3AUPHAurinia Pharmaceuticals2.6338 of 5 stars3.52.00.00.02.10.81.9SNDXSyndax Pharmaceuticals3.6286 of 5 stars3.51.00.04.44.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.00Hold$43.5078.21% UpsideAUPHAurinia Pharmaceuticals 3.00Buy$11.5039.56% UpsideSNDXSyndax Pharmaceuticals 2.90Moderate Buy$36.20155.83% UpsideCurrent Analyst Ratings BreakdownLatest IMU, SNDX, AMPH, and AUPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/21/2025AMPHAmphastar PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $32.003/20/2025SNDXSyndax PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$39.00 ➝ $41.003/4/2025SNDXSyndax PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$35.00 ➝ $39.003/4/2025SNDXSyndax PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $42.003/4/2025SNDXSyndax PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $51.002/4/2025AMPHAmphastar PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$66.00 ➝ $36.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$731.97M1.58$3.40 per share7.17$13.35 per share1.83AUPHAurinia Pharmaceuticals$235.13M4.79N/AN/A$2.63 per share3.13SNDXSyndax Pharmaceuticals$23.68M51.42N/AN/A$6.53 per share2.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$137.54M$3.068.147.422.1921.80%26.44%11.89%5/6/2025 (Estimated)AUPHAurinia Pharmaceuticals-$78.02M$0.05N/A14.71N/A-10.23%-4.41%-3.07%5/1/2025 (Estimated)SNDXSyndax Pharmaceuticals-$209.36M-$3.73N/AN/AN/AN/A-64.34%-57.72%5/6/2025 (Estimated)Latest IMU, SNDX, AMPH, and AUPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025AMPHAmphastar Pharmaceuticals$0.66N/AN/AN/A$173.29 millionN/A5/6/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.2419N/AN/AN/A$15.88 millionN/A5/1/2025Q1 2025AUPHAurinia Pharmaceuticals$0.09N/AN/AN/A$61.06 millionN/A3/3/2025Q4 2024SNDXSyndax Pharmaceuticals-$0.31-$1.10-$0.79-$1.10$86.32 million$7.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.823.432.61AUPHAurinia Pharmaceuticals0.175.605.11SNDXSyndax PharmaceuticalsN/A6.996.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%AUPHAurinia Pharmaceuticals36.83%SNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.10%AUPHAurinia Pharmaceuticals4.30%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,62047.50 million35.05 millionOptionableAUPHAurinia Pharmaceuticals300136.65 million137.02 millionOptionableSNDXSyndax Pharmaceuticals11086.04 million81.86 millionOptionableIMU, SNDX, AMPH, and AUPH HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Nantahala Capital Management LLCApril 30 at 8:14 AM | marketbeat.comNebula Research & Development LLC Buys 58,844 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 29 at 5:59 AM | marketbeat.comPropel Bio Management LLC Purchases 50,000 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 28 at 7:02 AM | marketbeat.comSyndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025April 28 at 7:00 AM | globenewswire.comEversept Partners LP Sells 3,761,913 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 24, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 3.6% - Should You Buy?April 23, 2025 | marketbeat.comAvoro Capital Advisors LLC Has $30.08 Million Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 23, 2025 | marketbeat.comJump Financial LLC Grows Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 21, 2025 | marketbeat.comAltium Capital Management LLC Makes New $4.89 Million Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 20, 2025 | marketbeat.comRenaissance Technologies LLC Acquires New Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 20, 2025 | marketbeat.comWalleye Capital LLC Has $4.82 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 19, 2025 | marketbeat.comSyndax management to meet with BTIGApril 16, 2025 | markets.businessinsider.comSei Investments Co. Sells 35,414 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 14, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Raised to "Sell" at StockNews.comApril 12, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6.6% - Here's What HappenedApril 11, 2025 | marketbeat.comExodusPoint Capital Management LP Lowers Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 11, 2025 | marketbeat.comSyndax price target lowered to $19 from $33 at BarclaysApril 10, 2025 | markets.businessinsider.comSyndax Pharmaceuticals (NASDAQ:SNDX) Hits New 12-Month Low - Here's WhyApril 9, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 8, 2025 | marketbeat.comRhenman & Partners Asset Management AB Sells 27,500 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 7, 2025 | marketbeat.comBryce Point Capital LLC Invests $417,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonS&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?By Jea Yu | April 23, 2025View S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?3 Robotics Stocks That Could Benefit From U.S. Manufacturing BoomBy Nathan Reiff | April 10, 2025View 3 Robotics Stocks That Could Benefit From U.S. Manufacturing BoomIMU, SNDX, AMPH, and AUPH Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$24.41 -0.09 (-0.37%) As of 04:00 PM EasternAmphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Aurinia Pharmaceuticals NASDAQ:AUPH$8.24 +0.12 (+1.48%) As of 04:00 PM EasternAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Syndax Pharmaceuticals NASDAQ:SNDX$14.15 +0.45 (+3.28%) As of 04:00 PM EasternSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
